VK2735 + Placebo + VK2735 Placebo + VK2735 Drug
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Weight Loss
Conditions
Weight Loss, NASH
Trial Timeline
Dec 14, 2021 → Dec 3, 2024
NCT ID
NCT05203237About VK2735 + Placebo + VK2735 Placebo + VK2735 Drug
VK2735 + Placebo + VK2735 Placebo + VK2735 Drug is a phase 1 stage product being developed by Viking Therapeutics for Weight Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT05203237. Target conditions include Weight Loss, NASH.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05203237 | Phase 1 | Completed |
Competing Products
20 competing products in Weight Loss